EOLS
Evolus, Inc. (NASDAQ)
Healthcare — Drug Manufacturers - Specialty & Generic
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Price History
Fundamentals
| Market Cap | $443.86M |
| P/E Ratio (TTM) | - |
| Forward P/E | 28.08 |
| EPS (TTM) | $-0.66 |
| Dividend Yield | - |
| Profit Margin | -14.39% |
| Revenue Growth | 6.70% |
| ROE | - |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | $14.67 |
| Analysts | 6 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 50.6 |
| Beta | 1.33 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $10.20 |
| 52-Week Low | $3.86 |
| 50-Day Avg | $6.32 |
| 200-Day Avg | $5.89 |
| Avg Volume | 826.2K |
| Volume | 567.6K |
Performance Analysis
NEUTRALEOLS presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:08 UTC
Back to Screener Export Report